Category: Pharma Industry

Group That Does Not Disclose Its Funding Releases White Paper Calling for 340B Reforms, Advocates Slam Report

October 24, 2024 Shannon Young, Associate Editor/Senior Writer Views

The Health Equity Collaborative called for 340B program overhauls in a new white paper.

An organization that describes itself as being “comprised of dozens of national, public health, patient advocacy and multicultural organizations,” but [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Growth in 340B Purchases Driven by Pharma Price Increases, Broader Healthcare Trends, Providers Say

October 22, 2024 William Newton, Associate Editor/Senior Writer Views

Providers say drugmaker price increases and broader healthcare trends drove last year's increase in total 340B purchases.

The growth in total 340B purchases last year was largely a result of drugmaker price increases and broader healthcare trends, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Lobbying Activity Did Not Slow Down in Q3, Federal Filings Suggest

October 22, 2024 Shannon Young, Associate Editor/Senior Writer Views

More than 360 firms reported lobbying on the 340B program between July 1 and Sept. 30.

The 340B drug discount program continued to be a hot topic for lobbyists in the third quarter of 2024, keeping [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Total 340B Drug Purchases Reached $66 Billion in 2023

October 18, 2024 William Newton, Associate Editor/Senior Writer Views

Total 340B purchases reached $66.3 billion in 2023, according to new HRSA data released Oct. 18.

Drug purchases under the 340B program reached $66.3 billion in 2023, marking a 24% increase over the $54 billion in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

State Contract Pharmacy Lawsuit Weekly Roundup: New Filings in Missouri, Minnesota

October 18, 2024 William Newton and Shannon Young, Associate Editor/Senior Writer Views

Key motions were recently filed in state contract pharmacy litigation in Missouri and Minnesota.

Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

PhRMA Pans Government’s Response to J&J’s 340B Rebate Proposal in Letter to HRSA Administrator

October 16, 2024 William Newton, Associate Editor/Senior Writer Views

PhRMA sent an Oct. 11 letter to HRSA criticizing the agency's opposition to J&J's 340B rebate proposal.

Pharmaceutical Research and Manufacturers of America (PhRMA) expressed “serious concerns” with the federal government’s opposition to Johnson & Johnson’s (J&J’s) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Health Leader Slams J&J Rebate Proposal, Urges Providers to ‘Remain Vigilant’ in Op-Ed

October 16, 2024 Shannon Young, Associate Editor/Senior Writer Views

Maureen Testoni, the president and CEO of 340B Health celebrated J&J’s retreat from a 340B rebate proposal in an Oct. 9 RACmonitor op-ed.

The head of an influential 340B hospital advocacy group claimed “victory” in the recent fight against Johnson & Johnson’s (J&J) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Providers Raise Caution on Claims Data Submission Requirements After 340B ESP Terms of Use Update Continues to Defer to Manufacturers

October 16, 2024 Shannon Young, Associate Editor/Senior Writer Views

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.

Editor’s Note: An earlier version of this story incorrectly suggested that an Oct. 4 update to 340B ESP’s terms of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Health Centers Urge Federal Appeals Court to Take Their Side in Case Alleging Drug Manufacturer Collusion on Contract Pharmacy Restrictions

October 16, 2024 Bella Czajkowski, National Correspondent Views

Two community health centers argued in a Sept. 30 filing with the U.S. 2nd Circuit Court of Appeals that diabetes drugmakers colluded to place contract pharmacy restrictions.

Two community health centers urged a federal appeals court to overturn the dismissal of their 340B antitrust lawsuit, arguing in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

CMS Inaction on IRA-340B Conflicts May Drive ‘Manufacturer-Friendly’ Compliance Models

October 10, 2024 William Newton, Associate Editor/Senior Writer Views

CMS has not assumed responsibility for “deduplicating” discounts that arise between the 340B program and the IRA's Medicare drug price negotiations.

Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

News Alert

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live